Status:

COMPLETED

Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia

Lead Sponsor:

Novexel Inc

Conditions:

Community Acquired Pneumonia

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults

Eligibility Criteria

Inclusion

  • Community acquired pneumonia

Exclusion

  • severe CAP
  • respiratory infections attributed to sources other than community acquired bacterial infection
  • concomitant pulmonary disease
  • history of hypersensitivity to study medication, macrolide or beta lactam antibiotics

Key Trial Info

Start Date :

October 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2008

Estimated Enrollment :

302 Patients enrolled

Trial Details

Trial ID

NCT00653172

Start Date

October 1 2007

End Date

November 1 2008

Last Update

January 9 2009

Active Locations (60)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (60 locations)

1

Clinica de Enfermedades Resp. "Miguel de Servet" SA

Santiago, Chile

2

Complejo Asistencial Barros Luco Trudeau

Santiago, Chile

3

Hospital de Urgencia Asistencia Publica

Santiago, Chile

4

Hospital Regional de Rancagua

Santiago, Chile

Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia | DecenTrialz